161 related articles for article (PubMed ID: 34783273)
1. Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R.
Hadfield MJ; Turshudzhyan A; Shalaby K; Reddy A
J Oncol Pharm Pract; 2022 Apr; 28(3):717-721. PubMed ID: 34783273
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
4. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
5. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
6. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
[TBL] [Abstract][Full Text] [Related]
7. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
8. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu Y; Miao J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):934-942. PubMed ID: 38163979
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Miyawaki E; Murakami H; Mori K; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Takahashi T
Jpn J Clin Oncol; 2020 May; 50(5):617-622. PubMed ID: 32211792
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
12. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
[TBL] [Abstract][Full Text] [Related]
13. [Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer
with EGFR Mutation].
Zhu Y; Dai Z
Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):742-749. PubMed ID: 36167460
[TBL] [Abstract][Full Text] [Related]
14. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
Front Immunol; 2022; 13():931718. PubMed ID: 35990690
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report.
Liu QX; Wei JG; Chen YY; Wang JF
Medicine (Baltimore); 2022 Aug; 101(33):e30099. PubMed ID: 35984168
[TBL] [Abstract][Full Text] [Related]
20. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]